BioSpace News Archive

Drug Development

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

Hutchison China MediTech Limited presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic at the 2019 European Society for Medical Oncology Congress.

October 1, 2019
·
11 min read
Biotech Bay

New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

Responses observed in patients with microsatellite stable (MSS) colorectal cancer, a disease not historically sensitive to checkpoint inhibition

October 1, 2019
·
6 min read
Policy

Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case

The payment of USD 14.3 million corresponds to the USD 11.6 million in damages plus interest awarded to Adocia in August 2018 by an American Arbitration Association Panel presiding over Adocia’s arbitration claims against Eli Lilly

October 1, 2019
·
5 min read
Deals

Centauri Therapeutics to Attend Scientific and Investor Conferences

Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences

October 1, 2019
·
1 min read
Business

4BIO Capital appoints Philippe Fauchet, OBE, as Venture Partner, Japan

4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces that it has appointed Philippe Fauchet, OBE, as a Venture Partner based in Japan.

October 1, 2019
·
3 min read
Poster discussion presentation at ESMO Congress highlights effective immune switch in MATINS patients with advanced solid tumours

TURKU – FINLAND, 30 September 2019 – Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today announces details from a poster discussion presentation held at the European Society of Medical Oncology 2019 Congress to showcase recent data from its ongoing MATINS study.

October 1, 2019
·
8 min read
Business

Synairgen plc: Interim results for the six months ended 30 June 2019

Synairgen plc, the respiratory drug discovery and development company, announces its unaudited interim results for the six months ended 30 June 2019.

October 1, 2019
·
3 min read
Biotech Beach

SkylineDx confirms positive results first independent validation skin cancer test

SkylineDx announced, during the European Society for Medical Oncology congress, that it successfully validated the performance of their skin cancer diagnostic test on the first, independent, European dataset.

October 1, 2019
·
2 min read
Deals

Novo Seeds co-leads €20 Million Series A Financing in STipe Therapeutics

Novo Seeds, the company creation team of Novo Holdings, announced that it has co-led the €20 million Series A financing round in STipe Therapeutics (STipe).

October 1, 2019
·
4 min read
Business

Research on Research Institute (RoRI) launches to enable more strategic, open, diverse, and inclusive research

We’re proud to announce the launch of the Research on Research Institute – an international consortium of research funders, academic institutions, and technologists working to champion the latest approaches to research on research.

October 1, 2019
·
8 min read